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Abstract
Tadalafil, a selective phosphodiesterase type 5 inhibitor, is a long-acting oral agent for the treatment of erectile dysfunction of
multiple etiologies. Although generalized tonic-clonic seizures were reported in a healthy man after taking tadalafil, the influence
of tadalafil on seizure susceptibility has not been studied so far. Therefore, the aim of the present study was to investigate the
effect of tadalafil on seizure threshold as well as on the activity of some first- and second-generation antiepileptic drugs in three
acute seizure tests in mice. The obtained results showed that tadalafil, at the highest dose tested (20 mg/kg), significantly
decreased the threshold for the first myoclonic twitch in the intravenous pentylenetetrazole (i.v. PTZ) seizure test. It did not
affect the threshold for generalized clonic seizure and forelimb tonus in the i.v. PTZ, for tonic hindlimb extension in the maximal
electroshock seizure threshold test, and for psychomotor seizure in the 6-Hz-induced seizure threshold test. Tadalafil did not alter
the anticonvulsant activity of any of the studied antiepileptic drugs in electrically induced seizure tests. Interestingly, tadalafil
potentiated the anticonvulsant activity of clonazepam and decreased the anticonvulsant activity of oxcarbazepine in the i.v. PTZ
test. These interactions were pharmacodynamic in nature, as tadalafil did not alter clonazepam and oxcarbazepine concentrations
both in serum and brain tissue. Furthermore, neither tadalafil alone nor its combinations with the studied antiepileptic drugs
produced any significant impairment of motor coordination (assessed in the chimney test), muscular strength (investigated in the
grip-strength test), and long-term memory (assessed in the passive avoidance task). In conclusion, tadalafil may increase the risk
of myoclonic seizure and decrease the anticonvulsant efficacy of oxcarbazepine. Further studies are warranted to evaluate the
safety of tadalafil usage in patients with epilepsy.
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Abbreviations
cGMP Cyclic guanosine 3′,5′-monophosphate
CS50 Current strength required to induce
seizure response in 50% of mice
ED50 Median effective dose
i.p. Intraperitoneally
IS Internal standard
i.v. Intravenously
MES Maximal electroshock seizure
MEST Maximal electroshock seizure threshold
N Newton
PDE5 Phosphodiesterase type 5
PTZ Pentylenetetrazole
SEM Standard error of the mean
Introduction
Erectile dysfunction, which is defined as a persistent or recur-
rent inability to obtain or maintain penile erection during sex-
ual intercourse, is a highly prevalent disorder that is expected
to reach 322 million cases by the year 2025 (McKinlay 2000).
It is closely associated with aging, lifestyle, and comorbid
diseases such as cardiovascular disease, hypertension, diabe-
tes mellitus, depression, or neurological disorders including
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epilepsy (Wyllie 2005). Erectile dysfunction has been estimat-
ed to occur in up to 65% of men suffering from epilepsy and
may be related to endocrine system abnormalities caused by
epileptic discharges or antiepileptic drug treatment, psychiat-
ric comorbidities, and psychosocial problems (Hamed et al.
2013; Vieira et al. 2015).
Oral drug treatment with phosphodiesterase type 5 (PDE5)
inhibitors is currently first-line therapy for erectile dysfunc-
tion. The three widely available drugs from this class are sil-
denafil citrate (Viagra®, Pfizer, USA), vardenafil (Levitra®;
Bayer AG, Germany), and tadalafil (Cialis®; Eli Lilly and
Company, USA). They share a similar mode of action.
Briefly, sexual arousal stimulates the nitric oxide (NO)/cyclic
guanosine 3′,5′-monophosphate (cGMP) signaling pathway in
the corpus cavernosum smooth muscle cells. PDE5 inhibitors
increase the intracellular level of cGMP by inhibiting its
breakdown, which improves smooth muscle relaxation and
prolongs penile erection (Coward and Carson 2008; Huang
and Lie 2013).
Although no clinical trials focusing on the effects of silden-
afil, vardenafil, or tadalafil on seizure activity were performed,
these medications are generally considered as safe and effec-
tive therapy in patients with epilepsy and co-existing erectile
dysfunction (Harden 2002; Matos et al. 2012). Nevertheless,
the safety of PDE5 inhibitors in epileptic patients is question-
able (Matos et al. 2012). Generalized tonic-clonic seizures
were first reported in two healthy men after taking sildenafil
(Gilad et al. 2002). Then, epileptic seizures were observed in
two men taking vardenafil (Koussa et al. 2006; Striano et al.
2006). Proconvulsant effect of sildenafil was also shown in
the intravenous pentylenetetrazole (i.v. PTZ) and bicuculline
seizure tests in mice (Montaser-Kouhsari et al. 2011;
Nieoczym et al. 2010b; Riazi et al. 2006). Sildenafil produces,
however, contradictory effects in animal models of seizure
and epilepsy. Its anticonvulsant action was observed in the
maximal electroshock seizure threshold (MEST) test
(Nieoczym et al. 2010a), in the 6-Hz-induced seizure test in
mice (Nieoczym et al. 2013), and in the amygdala kindling in
rats (Nieoczym et al. 2010b). Moreover, several studies
showed that sildenafil potentiated the activity of some antiep-
ileptic drugs in animal models of seizures (Nieoczym et al.
2010a, 2012a, 2012b, 2013). However, pharmacokinetic in-
teractions of sildenafil with carbamazepine and valproate raise
concern about the safety of its usage in combination with these
antiepileptic drugs (Nieoczym et al. 2010a). It seems that sil-
denafil may affect seizure susceptibility and the activity of
antiepileptic drugs. Thus, caution should be taken when pre-
scribing this PDE5 inhibitor in patients with epilepsy (Matos
et al. 2012; Nieoczym et al. 2010a).
Tadalafil has a markedly different molecular structure than
sildenafil and vardenafil, and these structural differences have
implications for the selectivity and pharmacokinetics of the
three PDE5 inhibitors. Sildenafil and vardenafil bind not only
to PDE5, but they are also quite potent PDE6 inhibitors. In
comparison, tadalafil is highly selective for PDE5, has low
affinity for PDE6, and potently inhibits PDE11—an enzyme
with an unclear physiological function (Coward and Carson
2008; Ferguson and Carson 2013). The most striking differ-
ence among the three PDE5 inhibitors is their duration of
action. Specifically, in humans, the half-lives of sildenafil
and vardenafil are at about 4 h, while tadalafil has much longer
half-life of approximately 17.5 h (Huang and Lie 2013).
Tadalafil’s longer half-life may pose a risk of long-lasting
side effects including increased seizure susceptibility (Matos
et al. 2012). It was shown that two days after single adminis-
tration, tadalafil produced detectable electroencephalographic
changes in up to 34% of healthymen (Okuyucu et al. 2009). In
animal studies, it accelerated seizure development in rats ex-
posed to hyperbaric oxygen (Demchenko et al. 2009).
Furthermore, tonic-clonic seizures in a healthy young man
following tadalafil intake were reported (Calabro et al.
2013). Thus, it seems that tadalafil may exert proconvulsive
effects. Considering the above data, we aimed to evaluate the
acute effect of tadalafil on the seizure threshold in three sei-
zure tests in mice, i.e., in the i.v. PTZ infusion test, the MEST
test, and the 6-Hz-induced psychomotor seizure test. In addi-
tion, the longer duration of action of tadalafil may increase the
risk for drug interactions. Since there is no data on the inter-
actions between tadalafil and antiepileptic drugs, we also in-
vestigated the influence of tadalafil on the activity of several
first- and second-generation antiepileptic drugs.
Materials and Methods
Animals
The experiments were performed on 1028 naïve male albino
Swiss mice weighing 25–30 g. The animals were purchased
from a licensed breeder (Laboratory Animals Breeding,
Ilkowice, Poland) and housed in groups of 8 in Makrolon
cages (37 cm × 21 cm × 14 cm) under strictly controlled lab-
oratory conditions (temperature maintained at 21–24 °C, rel-
ative humidity at 45–65%) with an artificial 12/12 h light/dark
regime (light on at 6:00 a.m.). A nutritionally balanced rodent
chow diet (Murigran, Agropol S.J., Motycz, Poland) and tap
water were continuously available. Animals were used in the
study after at least one week of acclimatization. All experi-
ments were performed between 8:00 a.m. and 3:00 p.m., after
a minimum 30-min adaptation period to the conditions kept in
the experimental room. The animals were randomly assigned
to the experimental groups. Each animal was used only once.
The study was performed under experimental protocols
approved by the Local Ethical Committee in Lublin.
Housing and experimental procedures were conducted in ac-
cordance with the European Union Directive of 22 September
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2010 (2010/63/EU) and Polish legislation acts concerning an-
imal experimentation. All efforts were made to minimize an-
imal suffering as well as the number of animals used in the
study.
Drugs
Tadalafil (kindly provided by Polpharma S.A., Starogard
Gdański, Poland), clonazepam (Clonazepamum, Polfa,
Warsaw, Poland), oxcarbazepine (Trileptal, Novartis,
Warsaw, Poland), tiagabine (Gabitril, Sanofi Winthrop,
Gentilly, France), carbamazepine (kindly provided by
Polpharma S.A., Starogard Gdański, Poland), and topiramate
(Topamax, Janssen-Cilag International NV, Beerse, Belgium)
were suspended in a 1% solution of Tween 80 (POCH,
Gliwice, Poland). Valproate (as sodium salt, Sigma-Aldrich)
was dissolved in normal saline. The pretreatment time for
tadalafil (90 min) was based on pharmacokinetic study re-
sults (see Fig. 1). Tiagabine and valproate were administered
15 min, clonazepam and oxcarbazepine 30 min, while carba-
mazepine and topiramate 60 min prior to the tests. All drug
solutions/suspensions were prepared freshly and administered
intraperitoneally (i.p.) at a volume of 0.1 ml per 10 g of body
weight. Control animals received respective vehicles only.
Pharmacokinetic Study of Tadalafil
For pharmacokinetic studies, tadalafil was administered at the
highest dose used in behavioral studies, i.e., 20 mg/kg i.p. The
mice were killed by decapitation 30, 60, 90, 120, and 240 min
after tadalafil administration. Blood samples of approximately
1 ml were rapidly harvested, collected into Eppendorf tubes,
and allowed to clot at room temperature. Subsequently, they
were centrifuged at 3000×g for 10 min and serum was
collected into polyethylene tubes. Simultaneously, the brains
were removed from skulls and washed with 0.9% NaCl. The
samples were kept at − 25 °C until analysis.
Tadalafil was measured in mouse serum (100 μl) and brain
homogenate (1 ml) by a HPLC method with fluorescence
detection. Brains were homogenized in distilled water (1:4,
w/v) with a tissue homogenizer TH220 (Omni International,
Inc., Warrenton, VA, USA). The extraction from both serum
and brain homogenate was performed using dichloromethane.
Prior to the extraction, all samples were spiked with
agomelatine solution (500 ng/ml) used as an internal standard
(IS) and serum samples were alkalized with 0.1 mol/l
Na2CO3, whereas 1 ml of concentrated NaCl (20 g/100 ml)
was added to brain homogenates and the samples were
vortexed for 15 s. After addition of the extraction reagent,
the samples were shaken for 20 min (IKA VXR Vibrax,
Germany) and centrifuged at 1000×g for 15 min (Universal
32, Hettich, Germany). The organic layers were transferred
into conical tubes and evaporated to dryness at 37 °C under
a gentle stream of nitrogen. The residue was dissolved in
100 μl of methanol and 20 μl of this solution was injected
into the LaChrom Elite HPLC system (Merck Hitachi, Japan)
consisting of an L-2130 pump, an L-2200 autosampler, an L-
2485 fluorescence detector, and an L-2350 column oven.
EZChrome Elite v. 3.2 (Merck Hitachi) software was used
for data acquisition. The separation was performed on a
LiChrospher® 100RP-18 column (250 × 4 mm, 5 μm)
coupled with a LiChroCART guard column (4.0 × 4.0 mm)
(Merck, Germany) with the same packing material. The mo-
bile phase consisted of acetonitrile and water mixed at 45:55
(v/v) ratio and it was pumped at a flow rate of 0.7 ml/min. The
column oven temperature was kept at 35 °C. The detector
excitation and emission wavelengths were set at 281 and
330 nm, respectively. Under these conditions, retention times
were 8 min for tadalafil and 10.1 min for IS. No interfering
peaks from biological matrices were observed. The calibration
curves were constructed by plotting the peak area ratios of the
analyte to IS versus corresponding concentrations of the ana-
lyte, and they were linear in the range of tested concentrations.
The limit of quantification was 10 ng/ml for serum and 25 ng/
g for brain homogenate. The assay was reproducible with low
intra- and inter-day variation (CV was less than 10%).
Intravenous Pentylenetetrazole Seizure Threshold
Test
At the appropriate time after drug suspensions or vehicle ad-
ministration, mice were placed in the cylindrical plastic re-
strainer (12-cm long, 3-cm inner diameter). The lateral tail
vein was catheterized with a 2-cm long 27-gauge needle at-
tached by polyethylene tubing PE20RW (Plastics One Inc.,
Roanoke, VA, USA) to a 5-ml plastic syringe containing 1%
aqueous solution of PTZ (Sigma-Aldrich). The syringe was
Fig. 1 Serum and brain concentrations of tadalafil in mice. Data are
presented as the mean ± SEM. Tadalafil (20 mg/kg) was injected i.p.
30, 60, 90, 120, and 240 min before mice decapitation. Experimental
groups consisted of 6–10 animals. Serum and brain concentrations of
tadalafil are expressed in ng/ml and ng/g, respectively
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mounted on a syringe pump (model Physio 22, Hugo Sachs
Elektronik–Harvard Apparatus GmbH, March-Hugstetten,
Germany). The accuracy of needle placement in the vein
was confirmed by appearance of blood in the tubing. The
needle was secured to the tail by an adhesive tape.
Following catheterization, mice were released from the re-
strainer and placed in a Plexiglas arena for behavioral obser-
vation. The PTZ solution was infused at a constant rate of
0.2 ml/min. The time intervals from the commencement of
PTZ infusion to the onset of each of three endpoints (the first
myoclonic twitch, generalized clonus with loss of the righting
reflex, and tonic forelimb extension) were recorded. The PTZ
infusion was stopped at the beginning of tonic seizures, which
were usually lethal for mice. All surviving animals were eu-
thanized immediately. In case of non-appearance of tonic sei-
zure, the infusion of PTZ was terminated at 180 s. For such
animals, the dose of PTZ in mg/kg infused till 180 s was taken
as the threshold dose. The seizure thresholds were calculated
separately for each endpoint using the following formula,
threshold dose of PTZ (mg/kg) = (infusion duration (s) ×
infusion rate (ml/s) × PTZ concentration (mg/ml) × 1000)/
body weight (kg), and were expressed as the dose of PTZ
(in mg/kg) needed to produce the first apparent sign of each
endpoint. Data obtained in the i.v. PTZ seizure threshold test
were presented as the amount of PTZ (in mg/kg) ± SEM
needed to produce the first apparent sign of each endpoint in
each experimental group.
Maximal Electroshock Seizure Test
Constant current stimuli (sine-wave pulses at 50 Hz for
200 ms) were applied via saline-soaked transcorneal elec-
trodes with the usage of rodent shocker (type 221; Hugo
Sachs Elektronik, Freiburg, Germany). During stimulation,
mice were restrained manually and immediately following
stimulation were placed in a transparent box for behavioral
observation for the presence or absence of seizure activity.
Tonic hindlimb extension, defined as the rigid extension of
the hindlimb that exceeds a 90° angle with the body, was taken
as an endpoint. Two experimental approaches to induce
electroconvulsions were used in the present study: (1) the
maximal electroshock seizure threshold (MEST) test that
employed stimulation at varied current intensities (7.6–
17.4 mA) and (2) the maximal electroshock seizure (MES)
test that employed stimulation at a fixed current intensity
(25 mA).
In the MEST test, the current intensity was established
according to an Bup-and-down^ method described by
Kimball et al. (1957). Current intensity was lowered or raised
by 0.06-log intervals depending on whether the previously
stimulated animal did or did not exert tonic hindlimb exten-
sion, respectively. The data obtained in groups of 20 animals
were used to determine the threshold current causing endpoint
in 50% of mice (CS50 with confidence limits for 95%
probability).
The MES test was performed in order to evaluate the anti-
convulsant potency of carbamazepine and topiramate admin-
istered alone or in combination with tadalafil. The animals (3–
4 groups, 8 animals/group) were injected with increasing
doses of antiepileptic drugs or their combinations with
tiagabine and then challenged with supramaximal MES stim-
ulus (25 mA). The percentage of mice failing to achieve
hindlimb extension was noted, and a log-probit method
(Litchfield and Wilcoxon 1949) was used to determine the
median effective doses (ED50) of antiepileptic drugs, i.e.,
doses (in mg/kg) that protect 50% of animals.
Six-Hertz Psychomotor Seizure Test
Square-wave alternating current stimuli (0.2-ms duration
pulses at 6 Hz for 3 s) were applied via saline-soaked corneal
electrodes using a Grass model CCU1 constant current unit
coupled to a Grass S48 stimulator (Grass Technologies,
Warwick, RI, USA). Before stimulation, the corneal elec-
trodes were wetted with saline to provide good electrical con-
tact. Mice were manually restrained during stimulation.
Immediately following the stimulation, mice were placed in
a transparent box for behavioral observation. Psychomotor
seizures were characterized by stun (fixed) posture, rearing,
forelimb clonus, twitching of the vibrissae, and elevated tail.
Lack of the features listed above or the resumption of normal
exploratory behavior within 10 s after stimulation were con-
sidered as the absence of seizures. Two experimental ap-
proaches to induce psychomotor seizures were used in the
present study: (1) the 6-Hz seizure threshold test that
employed stimulation at varied current intensities (10.0–
20.0 mA) and (2) the 6-Hz seizure test that employed
supramaximal stimulation at a fixed current intensity at
32 mA (Giordano et al. 2015, 2016).
In the 6-Hz seizure threshold test, the current intensity
values were chosen according to an Bup-and-down^ method
(Kimball et al. 1957). Each animal was stimulated only once
at any given current intensity that was lowered or raised by
0.06-log intervals depending on whether the previously stim-
ulated animal did or did not respond with convulsions. The
data obtained in groups of 20 animals were used to determine
the threshold current causing 6-Hz-induced seizures in 50% of
mice (CS50 with confidence limits for 95% probability).
The 6-Hz seizure test at fixed current intensity of 32 mA
was used to determine the protective potency of valproate and
tiagabine. Mice (3–4 groups, 8 animals/group) were injected
with increasing doses of antiepileptic drugs or their combina-
tions with tadalafil and then stimulated with supramaximal
current intensity of 32 mA. As in the MES test, a log-probit
method (Litchfield and Wilcoxon 1949) was used to deter-
mine the ED50 values of antiepileptic drugs in this test.
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Grip-Strength Test
The acute effects of tadalafil, antiepileptic drugs, and their
combinations with tadalafil on skeletal muscular strength in
mice were quantified in the grip-strength test. The grip-
strength apparatus (BioSeb, Chaville, France) consisted of a
steel wire grid (8 × 8 cm) connected to an isometric force
transducer. The animal was lifted by its tail so that it could
grasp the grid with its forepaws. The mouse were then gently
pulled backward until it released the grid and the maximal
force in newtons (N) exerted by the mouse before losing grip
was measured. The procedure was repeated three times and
the mean force exerted by each mouse before losing grip was
recorded. Themean force was then normalized to bodyweight
and expressed in mN/g ± SE.
Chimney Test
The chimney test was used to detect the motor deficits in mice
induced either by tadalafil, antiepileptic drugs, or combina-
tions of tadalafil with the studied antiepileptic drugs. In this
test, the inability of animals to climb backward up through a
Plexiglas tube (3 cm, inner diameter, × 30 cm, length) within
60 s is an indicator of motor impairment.
Step-Through Passive Avoidance Test
The step-through passive avoidance test was used for testing
the effect of antiepileptic drugs and their combination with
tadalafil on long-term memory impairments in mice. On the
first day before training, each animal was administered with
antiepileptic drug or its combination with tadalafil and placed
in the illuminated box (10 × 13 × 15 cm) connected via a guil-
lotine door to the dark box (25 × 20 × 15 cm) with an electric
grid floor. Entrance of the animal to the dark box was
punished by an adequate electric shock (0.6 mA foot shock
for 2 s). Twenty-four hours later, animals were placed again
into illuminated box and observed for up to 180 s. Mice that
avoided dark part were recognized to remember the task. The
retention time (the time that the mice took to enter to the dark
box) was noted and the results were presented as median la-
tencies (retention times; in seconds) with 25th and 75th
percentiles.
Determination of Clonazepam and Oxcarbazepine
Concentrations
Thirty minutes following administration of clonazepam or
oxcarbazepine with or without tadalafil, mice were decapitat-
ed to collect biological material for drug concentration mea-
surement in pharmacokinetic studies. Tadalafil was injected
90 min before decapitation. Blood was collected into
Eppendorf tubes and allowed to clot at room temperature.
Subsequently, it was centrifuged 3000×g for 10 min and se-
rum was collected into polyethylene tubes. Immediately after
the decapitation, brains were dissected from the skull and
washed with 0.9% NaCl. The samples were kept at − 25 °C
until analysis.
Plasma and brain concentrations of clonazepam were mea-
sured by a liquid chromatography tandem mass spectrometry
(LC-MS/MS) method. A simple liquid-liquid extraction with
a mixture of ethyl acetate:hexane (30:70, v/v) was used to
isolate clonazepam from serum (200 μl) or brain homogenate
(1 ml) in water (1:4, w/v). To each sample containing carba-
mazepine (50 ng/ml) as an IS, 5 ml of extraction solvent was
added and the samples were vigorously shaken for 20 min
(IKA VXR Vibrax, Germany). After centrifugation (1000×g
for 15 min), the organic layers were transferred into conical
tubes and evaporated to dryness at 37 °C under a stream of
nitrogen. The residue was dissolved in 100 μl of mobile phase
and 15 μl of this solution was injected onto the column. The
HPLC system (Agilent 1100, Agilent Technologies,
Waldbronn, Germany) consisted of a degasser, binary pump,
column oven, and an autosampler. Chromatographic separa-
tion was carried out on XBridge™ C18 analytical column
(3 × 50mm, 5 μm, Waters, Ireland) with the oven temperature
set at 30 °C. The mobile phase containing 0.1% formic acid in
acetonitrile (A) and 0.1% formic acid in water (B) was set at a
flow rate of 0.4 ml/min. Initial mobile phase composition was
95% B with a linear gradient to 20% B in the first 5 min, then
isocratic mode for 5 min with the following rapid change back
to 95% B in 0.1 min. The remaining time of elution was set at
95% B. The whole HPLC operation lasted 13 min.Mass spec-
trometric detection was performed on an Applied Biosystems
MDS Sciex (Concord, Ontario, Canada) API 2000 triple
quadrupole mass spectrometer equipped with an electrospray
ionization (ESI) interface. ESI ionization in the positive ion
mode was used for the ion production. The tandemmass spec-
trometer was operated at unit resolution in the selected reac-
tion monitoring (SRM) mode, monitoring the transition of the
protonated molecular ions m/z 316 to 270 and m/z 316 to 214
for clonazepam (first pair was used as an quantifier and the
second for the identity verification—qualifier) and m/z 237 to
194 for carbamazepine used as an IS. The mass spectrometric
conditions were optimized for clonazepam by continuous in-
fusion of the standard solution at the rate of 10 μl/min using a
Harvard infusion pump. The ion source temperature was
maintained at 450 °C. The ionspray voltage was set at
5500 V. The curtain gas (CUR) was set at 30 and the collision
gas (CAD) at 2. The optimal collision energy (CE) was 43 V.
The following parameters of ion path were used as the most
favorable ones: declustering potential (DP) at 26 V, focusing
potential (FP) at 330 V, and entrance potential (EP) at 4 V.
Data acquisition and processing were accomplished using the
Applied Biosystems Analyst version 1.6 software. The cali-
bration curves were constructed by plotting the ratio of the
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peak area of the studied drug to IS versus drug concentration
and generated by weighted (1/x) linear regression analysis.
The validated quantitation ranges for this method were within
the expected concentration ranges, namely from 1 to 200 ng/
ml for serum and 1–100 ng/g for brain tissue with accuracy
from 88.48 to 110.97% and from 88.29 to 106.51% for se-
rum and brain, respectively. The assays were reproducible
with low intra- and inter-day variation (coefficient of variation
less than 15%). No significant matrix effect was observed and
there were no stability-related problems during the routine
analysis of samples.
In order to determine oxcarbazepine concentrations, 100 μl
of serum sample diluted with 100 μl of water and 200 μl of
brain homogenate (1:4, w/v) in water were spiked with carba-
mazepine (1 μl/ml) employed as an IS. To brain homogenates,
NaCl solution (10 g/100ml) was added at a ratio of 1:1 and the
samples were vortexed for 15 s. Subsequently, 1 ml of ethyl
acetate was added to both serum samples and brain homoge-
nates and vigorously shaken for 20 min (IKA VXR Vibrax,
Germany). After centrifugation (TDX Centrifuge, Abbott
Laboratories, USA), the organic layers of brain samples were
transferred into conical tubes and evaporated to dryness at
37 °C under a stream of nitrogen. The organic layers separated
from serum samples were washed with 1 ml of 1 M HCl
before evaporation. The residues were dissolved in 100 μl of
acetonitrile and 5 μl of these solutions was injected into the
HPLC system. The HPLC system (Merck Hitachi, Darmstadt,
Germany) consisted of an L-7100 isocratic pump, an L-7200
autosampler, and a UV variable-wavelength K-2600 detector
(Knauer, Berlin, Germany). D-7000 HSM software was used
for data acquisition and processing. Analysis was performed
on a LiChrospher® 100RP-18 column (250 × 4 mm, 5 μm)
coupled with a LiChroCART guard column (4.0 × 4.0 mm)
(Merck, Germany) with the same packing material. The mo-
bile phase consisting of acetonitrile and water (36:64, v/v) was
pumped at a flow rate of 1 ml/min. Chromatographic analyses
were carried out at room temperature and the analytical wave-
length was 210 nm. In these conditions, the retention times
were 5.5 min for oxcarbazepine and 9.1 min for IS. The cal-
ibration curves were constructed by plotting the ratio of the
peak heights of the studied drug to IS versus drug concentra-
tion, and they were linear in the tested concentration range.
The relative error for accuracy and the coefficient of variation
for precision were less than 10%. No interfering peaks were
observed in the blank serum or brain homogenate and tadalafil
did not interfere with the assay.
Statistical Analysis
Data from seizure tests as well as from the grip-strength test
were analyzed using one-way analysis of variance (one-way
ANOVA) followed by the Tukey’s post hoc test. The Fisher’s
exact probability test was employed to compare the data from
the chimney test. The results obtained in the passive avoid-
ance task were compared with the Kruskal-Wallis test. Serum
and brain concentrations of clonazepam and oxcarbazepine
were analyzed using the unpaired Student’s t test.
p < 0.05 was considered statistically significant with 95%
confidence (GraphPad Prism version 5.03 for Windows,
GraphPad Software, San Diego, CA, USA).
Results
Brain and Serum Concentrations of Tadalafil
Brain and serum concentrations of tadalafil after its acute ad-
ministration (at a dose of 20 mg/kg i.p.) are shown in Fig. 1.
The highest serum concentration of tadalafil was noted 90min
after its injection. Likewise, tadalafil reached a peak brain
concentration at 90 min after administration.
Effect of Tadalafil on the Seizure Threshold in the i.v.
PTZ Test in Mice
The effect of tadalafil on the seizure threshold in the i.v. PTZ
test is shown in Fig. 2a–c (one-wayANOVA:F(4,50) = 17.98,
p < 0.0001 for myoclonic twitch; F(4,49) = 12.98, p < 0.0001
for generalized tonus; F(4,45) = 4.34, p = 0.005 for forelimb
tonus). Tadalafil administered at doses of 5 and 10 mg/kg did
not significantly affect the susceptibility of mice to the PTZ-
induced first myoclonic twitch. However, at the highest dose
tested, 20 mg/kg, it significantly decreased the threshold for
the first myoclonic twitch (Tukey’s post hoc test: p < 0.05 vs.
control group). No statistically significant changes in the
thresholds for the onset of generalized clonic seizures with
loss of righting reflex and forelimb tonic extension after
tadalafil (5–20 mg/kg) administration were observed. In con-
trast, valproate (a positive control) at a dose of 150 mg/kg
significantly increased the threshold for the onset of all the
studied endpoints (Tukey's post hoc test: p < 0.001 for myo-
clonic twitch and generalized clonus; p < 0.01 for forelimb
tonus).
Effect of Tadalafil on the Seizure Threshold
in the MEST Test
The influence of tadalafil on the threshold for the tonic
hindlimb extension in the MEST test is shown in Fig. 3a
(one-way ANOVA: F(4,42) = 25.05, p < 0.0001). Tadalafil
administered at doses of 5, 10, and 20 mg/kg had no signifi-
cant effect on the CS50 value in the MEST test. Positive con-
trol (valproate at 150 mg/kg) produced a significant increase
in the threshold for the hindlimb extension (Tukey’s post hoc
test: p < 0.001 vs. the control group).
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Effect of Tadalafil on the Seizure Threshold
in the 6-Hz Seizure Threshold Test
Figure 3b presents the effect of tadalafil on the threshold for
psychomotor seizure in the 6-Hz seizure test (one-way
ANOVA: F(4,42) = 30.34, p < 0.0001). The threshold for the
6-Hz-induced psychomotor seizure was not affected by
tadalafil administered at doses of 5, 10, and 20 mg/kg. In
comparison, positive control (valproate at 50 mg/kg) pro-
duced a significant increase in the psychomotor seizure
threshold (Tukey’s post hoc test: p < 0.001).
Effect of Tadalafil on the Activity of Clonazepam
and Oxcarbazepine in the i.v. PTZ Seizure Threshold
Test
Effect of clonazepam administered alone as well as in combi-
nation with tadalafil on the threshold for the first myoclonic
twitch in the i.v. PTZ test (one-way ANOVA: F(4,52) = 33.17,
p < 0.0001) is shown in Fig. 4a. Clonazepam injected alone at
a dose of 0.04 mg/kg significantly increased the PTZ thresh-
old for the first myoclonic twitch (Tukey’s post hoc test:
p < 0.001 vs. the control group). Co-administration of tadalafil
at doses of 5 and 10mg/kg did not cause any additional effects
on the threshold for myoclonic seizure as compared to clonaz-
epam alone.When injected a higher dose (20 mg/kg), tadalafil
augmented the anticonvulsant effect of clonazepam (Tukey’s
post hoc test: p < 0.01 vs. the clonazepam-treated group).
Effect of clonazepam administered alone as well as in com-
bination with tadalafil on the threshold for the onset of the
generalized clonus in the i.v. PTZ test (one-way ANOVA:
F(4,52) = 22.59, p < 0.0001) is shown in Fig. 4b.
Clonazepam injected alone at a dose of 0.04 mg/kg
Fig. 3 Effect of tadalafil on the seizure threshold in the MEST (a) and the
6-Hz-induced seizure test (b). Tadalafil and valproate (positive control)
were administered i.p. 90 and 15 min before the test, respectively. The
doses are shown on the abscissa. Control animals received 1% Tween 80.
Each experimental group consisted of 20 animals. Data are presented as
CS50 (in mA) values with upper 95% confidence limits. Each CS50 value
represents current intensity predicted to produce convulsions in 50% of
mice. ***p < 0.001 versus the control group (one-way ANOVA followed
by the Tukey’s post hoc test)
Fig. 2 Effect of tadalafil on the threshold for the first myoclonic twitch
(a), generalized clonus (b), and forelimb tonus (c) in the i.v. PTZ seizure
threshold test in mice. Tadalafil and valproate (positive control) were
administered i.p. 90 and 15 min before the test, respectively. The doses
are shown on the abscissa. Control animals received 1% Tween 80. Each
experimental group consisted of 10–13 animals. Each bar represents the
mean (mg/kg PTZ) + SEM. *p < 0.05, ***p < 0.001 versus the control
group (one-way ANOVA followed by the Tukey’s post hoc test)
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significantly increased the PTZ threshold for generalized clon-
ic seizure (Tukey’s post hoc test: p < 0.001 vs. the control
group), while co-administration of tadalafil at doses of 10
and 20 mg/kg significantly potentiated the anticonvulsant ac-
tivity of clonazepam against clonic seizure (Tukey’s post hoc
test: p < 0.05 and p < 0.01 vs. the clonazepam-treated group,
respectively). Joint administration of clonazepam and tadalafil
at the lowest dose tested, i.e., 5 mg/kg, did not cause any
additional effect on the PTZ threshold for generalized clonus
as compared to the clonazepam-treated group.
Effect of clonazepam administered alone as well as in
combination with tadalafil on the threshold for the onset
of forelimb tonus in the i.v. PTZ test (one-way ANOVA:
F (4 ,44) = 6.74, p < 0.001) i s shown in Fig . 4c .
Clonazepam injected alone at a dose of 0.04 mg/kg sig-
nificantly increased the PTZ threshold for the onset of
forelimb tonic extension (Tukey’s post hoc test: p < 0.05
vs. the control group). Tadalafil injected at doses of 10
and 20 mg/kg caused further increase in the threshold for
the PTZ-induced tonic seizure (Tukey’s post hoc test:
p < 0.01 and p < 0.001 vs. the control group, respectively).
The observed changes were not, however, statistically sig-
nificant in comparison to clonazepam alone.
Effect of oxcarbazepine administered alone as well as in
combination with tadalafil on the threshold for the onset of the
first myoclonic twitch in the i.v. PTZ test (one-way ANOVA:
F(4,51) = 11.62, p < 0.0001) is shown in Fig. 4d.
Oxcarbazepine injected alone at a dose of 25 mg/kg signif-
icantly raised the threshold for myoclonic twitch (Tukey’s
post hoc test: p < 0.001 vs. the control group). Statistically
significant raise in the threshold for myoclonic seizures was
also observed in groups of animals treated with combina-
tion of oxcarbazepine and tadalafil at 5 and 10 mg/kg.
When given at 10 mg/kg, tadalafil abolished the anticon-
vulsant effect of oxcarbazepine (p > 0.05 as compared to
the control group).
Effect of oxcarbazepine administered alone as well as in
combination with tadalafil on the threshold for the onset of the
Fig. 4 Effect of clonazepam and
oxcarbazepine administered alone
and in combination with tadalafil
on the threshold for the first
myoclonic twitch (a, d),
generalized clonus (b, e), and
forelimb tonus (c, f) in the i.v.
PTZ seizure threshold test in
mice. Tadalafil was administered
90 min, while clonazepam and
oxcarbazepine 30 min before the
test. All the drugs were injected
i.p. The doses are shown on the
abscissa. Control animals
received vehicles only. Each
experimental group consisted of
8–13 animals. Each bar represents
the mean (mg/kg PTZ) + SEM.
*p < 0.05, **p < 0.01,
***p < 0.001 versus the control
group; #p < 0.05, ##p < 0.01
versus the clonazepam-treated
group (one-way ANOVA follow-
ed by the Tukey’s post hoc test)
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generalized clonus in the i.v. PTZ test (one-way ANOVA:
F(4,51) = 10.20, p < 0.0001) is shown in Fig. 4e.
Oxcarbazepine administered alone and in combination with
tadalafil at 5 mg/kg significantly raised the threshold for gen-
eralized clonic seizure (p < 0.01 and p < 0.001, respectively).
No such effect was observed when oxcarbazepine was co-
administered with tadalafil at doses of 10 and 20 mg/kg
(p > 0.05 vs. the control group).
Effect of oxcarbazepine administered alone as well as in
combination with tadalafil on the threshold for the onset of
forelimb tonus in the i.v. PTZ test (one-way ANOVA:
F (4 ,47 ) = 4 .50 , p = 0 .004) i s shown in F ig . 4 f .
Oxcarbazepine injected alone significantly increased the
threshold for the PTZ-induced forelimb tonus (p < 0.01 vs.
control group). Co-administration of tadalafil at all doses test-
ed did not affect the anticonvulsant potency of oxcarbazepine
against tonic forelimb extension (p < 0.05 vs. control group).
Effect of Tadalafil on the Activity of Carbamazepine
and Topiramate in the MES Test
Effect of tadalafil on the anticonvulsant potency of carbamaz-
epine and topiramate in the MES test is shown in Fig. 5a, b
(one-way ANOVA: F(3,100) = 0.25, p = 0.862 for panel a and
F(3,76) = 0.303, p = 0.823 for panel b). Carbamazepine and
topiramate administered alone produced anticonvulsant effect
against maximal electroshock-induced seizure. Tadalafil
injected at doses of 5, 10, and 20 mg/kg had no significant
effect on the anticonvulsant action of carbamazepine and
topiramate in the MES test in mice.
Effect of Tadalafil on the Activity of Valproate
and Tiagabine in the 6-Hz Seizure Test
The influence of tiagabine on the anticonvulsant potency of
valproate and tiagabine in the 6-Hz seizure test is shown in
Fig. 6a, b (one-way ANOVA: F(3,92) = 0.83, p = 0.481 for
panel a and F(3,60) = 0.84, p = 0.477 for panel b). Both
valproate and tiagabine administered alone exhibited anticon-
vulsant activity against the 6-Hz-induced seizure. Tadalafil
injected at doses of 5, 10, and 20 mg/kg did not affect signif-
icantly the ED50 values of both valproate and tiagabine in the
6-Hz seizure test.
Effects of Tadalafil on Motor Coordination
and Muscular Strength in Mice
The acute effects of tadalafil (5–20 mg/kg) on the neuromus-
cular strength and motor coordination in mice are shown in
Table 1. There were no significant impairments of motor co-
ordination in the chimney test (Fisher’s exact test: p > 0.05).
Likewise, tadalafil at any dose tested did not significantly
affect the neuromuscular strength in mice, as determined in
the grip-strength test (one-way ANOVA: F(4,44) = 0.36, p =
0.839).
Effects of Tadalafil in Combination with Antiepileptic
Drugs on Muscular Strength, Motor Coordination,
and Long-Term Memory in Mice
Neither antiepileptic drugs alone nor their combinations
with tadalafil at a dose of 20 mg/kg affected significantly
motor coordination, as determined in the chimney test
(Fisher’s test: p > 0.05 for all experimental groups;
Table 2, column I). There were also no significant chang-
es in neuromuscular strength, as assessed in the grip-
strength test (one-way ANOVA: F(4,44) = 2.455, p =
0.060 for group A; F(4,45) = 1.113, p = 0.362 for group
B; F(4,45) = 1.628, p = 0.184 for group C, Table 2, col-
umn II). Likewise, no alterations in long-term memory in
mice treated with antiepileptic drugs or their combina-
tions with tadalafil were observed, as assessed in the
passive avoidance task (Kruskal-Wallis test: KW =
4.317, p = 0.365 for group A; KW = 3.594, p = 0.464 for
group B; KW = 7.772, p = 0.100 for group C; Table 3,
column III).
Fig. 5 Effect of tadalafil on the anticonvulsant potency of carbamazepine
(a) and topiramate (b) in theMES test in mice. Tadalafil was administered
90 min, carbamazepine 30 min, and topiramate 60 min prior to the test.
All the drugs were injected i.p. Control animals received an antiepileptic
drug and 1% Tween 80 instead of tadalafil. Each experimental group
consisted of 24–32 animals. Each ED50 (+ SEM) value represented a
dose of an antiepileptic drug predicted to protect 50% of mice tested
against maximal electroshock-induced convulsions
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Effect of Tadalafil on Clonazepam and Oxcarbazepine
Concentrations
The influence of tadalafil on serum and brain concentrations
of clonazepam and oxcarbazepine is shown in Table 3. Co-
administration of tadalafil at a dose of 20 mg/kg and clonaz-
epam at a dose of 0.04 mg/kg did not change clonazepam
concentrations in serum and brain tissue (Student’s t test:
p = 0.164 and p = 0.460, respectively). Likewise, no changes
in serum and brain concentrations of oxcarbazepine in mice
co-administered with tadalafil at 20 mg/kg and oxcarbazepine
at 25mg/kg were observed (Student’s t test: p = 0.996 and p =
0.442, respectively).
Discussion
Although tadalafil was developed initially to act as a vasodi-
lator in peripheral tissues, it also exerts central effects because
of its ability to cross the blood-brain barrier and the presence
of PDE5 in different brain regions (Peixoto et al. 2015). The
involvement of the NO/cGMP/PDE5 pathway in the patho-
physiology of epilepsy (Ferraro and Sardo 2004; Riazi et al.
2006) raises the possibility that tadalafil can affect seizure
activity, but despite the widespread use of tadalafil, its influ-
ence on seizure susceptibility has not been studied. Here, we
investigated the effect of acute treatment with tadalafil on
seizure thresholds in three different seizure tests in mice that
are widely used in antiepileptic drugs research and develop-
ment (Löscher 2011; Mandhane et al. 2007).
Garcia-Barroso and co-workers (2013) demonstrated for the
first time that tadalafil penetrates into the brain after oral ad-
ministration and it reaches concentrations that may lead to a
marked inhibition of PDE5 within different brain structures. In
order to characterize the ability of tadalafil to cross the blood-
brain barrier after intraperitoneal route of administration in
mice, we performed a pilot pharmacokinetic study in which
we showed that changes in serum and brain concentrations of
tadalafil followed a similar time-course pattern with the maxi-
mum concentrations reached at about 90 min post injection.
The pretreatment time of 90 min for tadalafil was used in all
subsequent experiments to study its acute effects on seizure
thresholds. The timed i.v. PTZ infusion test was employed to
investigate the effect of tadalafil on chemically induced seizure.
This test is considered as extremely sensitive parametric meth-
od for assessing seizure thresholds in rodents (White 1998). It is
widely accepted that proconvulsant activity of PTZ is at least
partially mediated by its ability to block the chloride ion chan-
nel in the GABAA receptor complex and the PTZ seizure
thresholds are particularly sensitive to compounds that affect
GABAergic neurotransmission (Löscher 2009). The obtained
results showed that tadalafil did not affect the threshold for the
onset of both the generalized clonic seizure with the loss of
righting reflex and the tonic forelimb extension in the i.v.
PTZ test. Interestingly, tadalafil at the highest dose tested (i.e.,
20 mg/kg) significantly decreased the threshold for the first
myoclonic twitch. Myoclonus is defined as involuntary, sud-
den, and brief muscle jerks that are reported in a number of
different diseases including myoclonic epilepsy. In addition,
myoclonic jerks have been described as an adverse effect of
many drugs. Themechanism underlying myoclonus is not fully
Table 1 Effect of tadalafil on motor coordination and neuromuscular
strength in mice
Treatment
(mg/kg)
Impairment of motor
performance (%)
Neuromuscular
strength (mN/g)
Control 0 26.53 ± 0.64
Valproate (150) 0 26.19 ± 1.09
Tadalafil (5) 0 26.05 ± 1.09
Tadalafil (10) 0 26.95 ± 0.45
Tadalafil (20) 10 27.45 ± 1.25
Data are presented as a percentage of animals showing motor coordina-
tion impairment in the chimney test and as means ± SEM grip strengths in
millinewtons per gram of mouse body weight (mN/g) from the grip-
strength test, assessing skeletal muscular strength in mice. Each experi-
mental group consisted of 10 animals. The results from the grip-strength
test were analyzed with one-way ANOVA. Statistical analysis of data
from the chimney test was performed with the Fisher’s exact probability
test
Fig. 6 Effect of tadalafil on the anticonvulsant potency of valproate (a)
and tiagabine (b) in the 6-Hz seizure test in mice. Tadalafil was adminis-
tered 90 min, while valproate and tiagabine 15 min prior to the test. All
the drugs were injected i.p. Control animals received an antiepileptic drug
and 1% Tween 80 instead of tadalafil. Each experimental group consisted
of 24 animals. Each ED50 (+ SEM) value represented a dose of an anti-
epileptic drug predicted to protect 50% of mice tested against 6-Hz-
induced psychomotor seizure
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understood but it is generally considered that alterations of the
GABAA receptor activity at different points along the neural
axis may contribute to myoclonic jerks (Matsumoto et al.
2000). Of note, GABAA receptor antagonists, such as PTZ or
bicuculline, produce myoclonus in animal models (Wheless
and Sankar 2003). There is no data on the direct influence of
tadalafil on the GABA-mediated transmission. However, sev-
eral lines of evidence demonstrated the involvement of the NO/
cGMP pathway in the GABA-mediated transmission (Prast and
Philippu 2001). Since tadalafil acts as a modulator of the NO/
cGMP/PDE5 signaling pathway, it is possible that it may affect
GABA release and/or GABAA receptor activity. Targeting
PDE5 with tadalafil elevates intracellular cGMP level.
Accumulation of cGMP may lead to the activation of protein
kinase G and subsequent phosphorylation of the GABAA re-
ceptor subunits, which results in reduced GABA-mediated
neuronal inhibition (Wang and Robinson 1997). It should fur-
thermore be noted that PTZ increases cGMP level in several
brain structures (such as cerebral cortex, hippocampus, stria-
tum, and cerebellum), which supports the hypothesis that
cGMP plays a role in the initiation and propagation of PTZ-
induced seizures (Ferrendelli et al. 1980). Thus, it seems that
decreased seizure threshold for myoclonic twitch following
tadalafil administration could have resulted from increased
cGMP concentration and subsequent decrease in GABA-
mediated neuronal inhibition. Additionally, PTZ-induced inhi-
bition of the GABAergic transmission leads to the enhance-
ment of glutamatergic neuronal activity (Watanabe et al.
2013). The glutamate-mediated excitatory transmission seems
to be controlled by cGMP in biphasic manner because in-
creased cGMP level suppresses glutamate release while very
high cGMP concentrations increase the release of glutamate
Table 2 Effects of antiepileptic drugs and their combinations with tadalafil on motor performance in the chimney test, neuromuscular strength in the
grip-strength test, and long-term memory in the passive avoidance task in mice
Treatment
(mg/kg)
I. Impairment of motor
performance (%)
II. Neuromuscular
strength (mN/g)
III. Retention
time (s)
A. Control 0 29.77 ± 0.64 180 (141.8; 180)
Clonazepam (0.04) 0 31.31 ± 1.49 167 (68.3; 180)
Clonazepam (0.04) + tadalafil (20) 10 29.06 ± 1.20 165.5 (72; 180)
Oxcarbazepine (25) 0 30.23 ± 1.16 170 (28.5; 180)
Oxcarbazepine (25) + tadalafil (20) 0 26.32 ± 1.37 180 (90.5; 180)
B. Control 0 28.56 ± 0.97 179 (84.75; 180)
Carbamazepine (9.65) 0 28.38 ± 1.33 180 (105; 180)
Carbamazepine (9.65) + tadalafil (20) 0 30.71 ± 1.31 180 (180; 180)
Topiramate (26.21) 0 27.76 ± 1.61 180 (110.3; 180)
Topiramate (26.21) + tadalafil (20) 10 27.05 ± 1.22 148 (98.0; 180)
C. Control 0 29.11 ± 1.90 180 (37.75; 180)
Valproate (137.96) 0 29.99 ± 1.61 175 (35.75; 180)
Valproate (137.96) + tadalafil (20) 0 26.01 ± 1.49 180 (180; 180)
Tiagabine (0.90) 0 25.50 ± 0.92 180 (170; 180)
Tiagabine (0.90) + tadalafil (20) 0 30.00 ± 2.37 106 (28.5; 180)
Data are presented as a percentage of animals showingmotor coordination impairment in the chimney test, as mean ± SEMgrip strengths inmillinewtons
per gram of mouse body weight (mN/g) from the grip-strength test, assessing skeletal muscular strength in mice, and as median retention time (in s; with
25th and 75th percentiles in parentheses) from the passive avoidance task, assessing long-termmemory inmice. Each experimental group consisted of 9–
10 animals. The results from the grip-strength test were analyzedwith one-wayANOVA. Statistical analysis of data from the chimney test was performed
with the Fisher’s exact probability test. Non-parametric Kruskal-Wallis ANOVA test was used to analyze the results from the passive avoidance task
Table 3 Effect of tadalafil on
serum and brain concentrations of
clonazepam and oxcarbazepine
Treatment (mg/kg) Serum Brain
Clonazepam (0.04) 3.96 ± 0.68 ng/ml 16.36 ± 3.13 ng/g
Clonazepam (0.04) + tadalafil (20) 5.23 ± 0.56 ng/ml 18.86 ± 1.09 ng/g
Oxcarbazepine (25) 10.27 ± 0.70 μg/ml 10.13 ± 0.47 μg/g
Oxcarbazepine (25) + tadalafil (20) 10.27 ± 0.48 μg/ml 10.79 ± 0.69 μg/g
Tadalafil was administered 90minwhile clonazepam and oxcarbazepinewere administered 30min before the test.
Data are presented as means ± SEM. Each experimental group consisted of 8–10 animals. Serum and brain
concentrations of antiepileptic drugs were analyzed with the Student’s t test
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(Prast and Philippu 2001). Hence, tadalafil at a relatively high
dose of 20 mg/kg could have also stimulated the release of
excitatory neurotransmitter—glutamate. The possible risk of
increased susceptibility to myoclonic seizure after tadalafil
treatment as well as the mechanism underlying this phenome-
non deserves further investigation.
Despite the fact that tadalafil exerted proconvulsant activity
with regard tomyoclonic seizures, it did not affect the thresholds
for electrically induced seizures. It failed to affect the threshold
for both the tonic hindlimb extension and psychomotor seizures
in the MEST and the 6-Hz-induced seizure test, respectively.
Psychomotor seizures are believed to emanate from the limbic
system (Barton et al. 2001), especially from the hippocampus
and amygdala (Lucchi et al. 2017; Giordano et al. 2015, 2016).
Clonus originates from forebrain structures, whereas tonic sei-
zures involve brainstem (White et al. 2009). The lack of effect of
tadalafil on clonic and tonic seizures (in both the i.v. PTZ and the
MEST tests) as well as on the psychomotor seizures suggests
that the changes in cGMP level were not sufficient to modulate
the inhibitory and/or excitatory neurotransmission within the
aforementioned brain structures. Alas, the changes in cGMP
concentration in different brain areas after tadalafil administra-
tion have not yet been determined.
The influence of tadalafil on the efficacy of antiepileptic
drugs has not been studied so far. For this reason, we also
aimed to evaluate the effect of tadalafil on several first- and
second-generation antiepileptic drugs. The obtained results
showed that tadalafil did not alter the anticonvulsive activity
of carbamazepine and topiramate (against the maximal
electroshock-induced seizures) as well as valproate and
tiagabine (against the 6-Hz-induced psychomotor seizures).
In the i.v. PTZ seizure threshold test, tadalafil potentiated the
protective activity of clonazepam against myoclonic and gen-
eralized clonic seizures. In contrast, tadalafil decreased the
protective activity of oxcarbazepine against PTZ-induced
myoclonic and generalized clonic seizures. The interactions
between tadalafil and clonazepam or oxcarbazepine may have
pharmacodynamic and/or pharmacokinetic basis .
Pharmacokinetic interaction occurs when one drug alters the
concentration of the other drug by affecting its absorption,
distribution, metabolism, or excretion (Corrie and Hardman
2014). To evaluate the potential pharmacokinetic
clonazepam-tadalafil and oxcarbazepine-tadalafil interactions,
brain and serum concentrations of clonazepam or
oxcarbazepine were determined using HPLC methods. No
alterations of brain and serum concentrations of the two anti-
epileptic drugs were noted, which suggests that the changes of
their anticonvulsant activity in the i.v. PTZ test were most
likely related to pharmacodynamic interactions with tadalafil.
Briefly, pharmacodynamic interaction occurs when one drug
alters the effect of another drug without changes in its concen-
tration and it involves antagonism or addition of pharmaco-
logical properties of the two drugs (Corrie and Hardman
2014). Clonazepam, the first-generation antiepileptic drug
from the benzodiazepine group, facilitates GABAergic neuro-
transmission by a direct effect on GABAA receptors. The po-
tentiation of anticonvulsant activity of clonazepam by tadalafil
in the i.v. PTZ test is rather an unexpected result because
tadalafil was shown to decrease the threshold for myoclonic
twitch in this test. Oxcarbazepine belongs to the newer gener-
ation of antiepileptic drugs. Its mechanism of action is mostly
related to the blockade of voltage-sensitive Na+ channels,
which reduces high-frequency repetitive firing of neurons.
Oxcarbazepine also enhances K+ current. Moreover,
oxcarbazepine and its active metabolite inhibit high-voltage-
activated N-type Ca2+ channels and reduce glutamatergic neu-
rotransmission in rat cortex (Łuszczki et al. 2003). There are
no direct evidence that tadalafil affects GABAergic and glu-
tamatergic transmission and those ion channels that are in-
volved in initiation, propagation, and amelioration of seizures.
We can only speculate that tadalafil (as a NO/cGMP/PDE5
modulator) may modulate inhibitory and excitatory neuro-
transmission and/or some ion channels functioning.
Tadalafil-induced changes in anticonvulsant activity of clo-
nazepam and oxcarbazepine may be a result of their interac-
tions with different cellular targets. Further studies are needed
to characterize the basis of these interactions. Other experi-
mental models of seizures or epilepsy should be used as well.
Additionally, it would be advisable to test the combination of
an ineffective dose of tadalafil with an ineffective dose of
clonazepam to confirm the presence of a synergistic interac-
tion between them. Interactions of tadalafil with other benzo-
diazepines and positive allosteric modulators of the GABAA
receptor should be also studied in future.
It is worth mentioning that neither tadalafil alone nor its
combinations with the studied antiepileptic drugs produced
any acute side effects as determined in the chimney test, the
grip-strength test, and the passive avoidance task.
Sildenafil, the first approved PDE5 inhibitor, is the most
extensively studied drug from this class. When compared the
effects of sildenafil and tadalafil in the three seizure tests
employed in the present study, we can see that tadalafil has
much weaker influence on the seizure thresholds. It only de-
creased the seizure threshold for myoclonus twitch in the i.v.
PTZ test, whereas sildenafil reduced the threshold for clonic
seizure in the i.v. PTZ (Nieoczym et al. 2010b; Riazi et al.
2006), raised the threshold for tonic hindlimb extension in the
MEST (Nieoczym et al. 2010a), and raised the threshold for
the 6-Hz-induced psychomotor seizure in mice (Nieoczym
et al. 2013). Furthermore, the influence of sildenafil and
tadalafil on the anticonvulsant activity of antiepileptic drugs
is quite different. Specifically, sildenafil raised the ED50 value
of carbamazepine and topiramate in the MES test (Nieoczym
et al. 2010a) as well as valproate and tiagabine in the 6-Hz
seizure test (Nieoczym et al. 2013), while tadalafil did not. On
the contrary, sildenafil did not affect the anticonvulsant
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potency of clonazepam in the subcutaneous PTZ test
(Nieoczym et al. 2012a) and it increased the activity of
oxcarbazepine in the MES test (Nieoczym et al. 2010a). It is
also worth mentioning that the interactions of sildenafil with
carbamazepine and valproate were shown to be, at least in
part, pharmacokinetic in nature (Nieoczym et al. 2010a).
To conclude, our data suggest that tadalafil may increase
myoclonic seizure susceptibility but it should not potentially
increase the risk of clonic and tonic seizures. Tadalafil may
produce some beneficial pharmacodynamics interactions with
clonazepam but its co-administration with oxcarbazepine
should be rather avoided. However, because our observations
have been made in animals, caution should be taken when
extrapolating the present results to humans as the response
to tadalafil and its influence on the activity of antiepileptic
drugs may vary between mice and human subjects. Further
studies are required to estimate the risk/benefit ratio of
tadalafil usage in epileptic patients.
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